Interim Analysis of the Protégé Paclitaxel-Eluting Balloon in Real-World Practice (PEARL) Registry

Selina Vlieger1, Jin M. Cheng2, Simon Dello3, Bas Scholzel4, Auke P.J.D. Weevers1, Martijn E. Meuwissen1, Jawed Polad1, Ben Gho4, Rohit M. Oemrawsingh1, Peter den Heijer1, Alexander J.J. IJsselmuidd1.

1Albert Schweitzer hospital, department of Cardiology, Dordrecht, the Netherlands.
2Amphia hospital, department of Cardiology, Breda, the Netherlands.
3Jeroen Bosch hospital, department of Cardiology, Den Bosch, the Netherlands.
4Zuyderland hospital, department of Cardiology, Heerlen, the Netherlands.

*Corresponding Author: A.J.J. IJsselmuidd, Amphia hospital, department of Cardiology, Breda, the Netherlands.

Received Date: January 22, 2021; Accepted Date: February 01, 2021; Published Date: February 08, 2021

Citation: Selina Vlieger, Jin M. Cheng, Simon Dello, Bas Scholzel, Alexander J.J. IJsselmuidd, et al (2021) Interim Analysis of the Protégé Paclitaxel-Eluting Balloon in Real-World Practice (PEARL) Registry. J. Clinical Cardiology and Cardiovascular Interventions, 4(3); Doi:10.31579/2641-0419/133

Copyright: © 2021 A.J.J. IJsselmuidd. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: drug-eluting balloon; percutaneous coronary intervention; paclitaxel- eluting balloon; real-world data.

Introduction

Percutaneous coronary intervention (PCI) is often performed with implantation of a drug-eluting stent (DES) [1]. However, stent implantation may be less desirable for recurrent in-stent restenosis and for specific lesion characteristics such as small vessel disease and coronary ostia. Randomized controlled trials have shown promising results for the use of a drug-eluting balloon (DEB) in these indications [2-4], but data on DEB use in real-world practice are still scarce.

The Protégé DEB (Wellinq, Leek, the Netherlands) features an innovative balloon design in which the drug component is encapsulated in the balloon folds and is only exposed upon inflation. Hereby, DEB handling and tight lesion crossing will not lead to premature drug release. Predilation may not be required with this DEB as, besides a compliant version, the DEB is also available in a non-compliant version. The Paclitaxel-Eluting Angioplasty Balloon in the Real-World (PEARL) Registry aims to evaluate safety and efficacy of the Protégé DEB in real-world practice.

Methods and Results

This interim analysis includes the first 200 consecutive patients in the registry. Patients were included in four hospitals in the Netherlands. Mean age was 65.7 ±10.6 years and 71% were men. Patients had a high cardiovascular risk profile with diabetes in 25%, hypertension in 59%, history of myocardial infarction in 64%, and history of prior PCI in 89% and coronary artery bypass grafting in 19%. Indication for PCI was ST-elevation myocardial infarction in 10% and non-ST-elevation acute coronary syndrome in 35%. DEB was primarily used for in-stent restenosis in 73.5% of patients and for denovo lesions in 26.5% of patients.

A total of 242 lesions were treated with DEB with lesion distribution in the left main in 2%, left anterior descending in 39%, left circumflex in 20%, right coronary artery in 30% and bypass graft in 9%. The majority of lesions had a high complexity with 34% classified as type B2 and 46% classified as type C. Mean lesions length was 21.0 ±17 mm and mean diameter was 2.8 ±0.7 mm. Predilation was performed in 67%. Non-compliant DEB was used in 38%. Average inflation time was 53±19 seconds at a mean atmosphere of 14±4 atm. DEB related procedural complications were low (6.5%), mostly consisting of coronary dissection (n=12). Bail-out stenting was required in 6.5%. Device failure only occurred in 2 patients (balloon burst). Final angiographic and clinical success was achieved in all patients.

None of the patients had a major adverse cardiac event (MACE) during hospitalization (Table 1).

<table>
<thead>
<tr>
<th>In-hospital events</th>
<th>N=200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite MACE</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Procedural complications</td>
<td></td>
</tr>
<tr>
<td>DEB related complications</td>
<td>13 (6.5%)</td>
</tr>
<tr>
<td>Bail-out stenting</td>
<td>13 (6.5%)</td>
</tr>
<tr>
<td>Device failure</td>
<td>2 (1.0%)</td>
</tr>
<tr>
<td>Events at 6 months</td>
<td></td>
</tr>
<tr>
<td>Composite MACE</td>
<td>20 (10%)</td>
</tr>
<tr>
<td>Cardiac death</td>
<td>4 (2%)</td>
</tr>
<tr>
<td>Target vessel myocardial infarction</td>
<td>6 (3%)</td>
</tr>
<tr>
<td>Target lesion revascularization</td>
<td>10 (5%)</td>
</tr>
</tbody>
</table>

Table 1: Clinical outcomes after PCI with paclitaxel DEB

PCI: Percutaneous Coronary Intervention, DEB: drug-eluting balloon, MACE: Major Adverse Cardiac Events
At six months, MACE occurred in 20 patients (10.0%), consisting of target lesion revascularization (TLR) in 5%, target vessel myocardial infarction in 3%, and cardiac death in 2%.

**Discussion**

When comparing data with that of randomized controlled trials [2-4], it should be noted that the patients in the PEARL registry seem to have a higher cardiovascular risk profile and more often present with acute coronary syndrome, lesions seem to have higher complexity and predilation was performed less frequently. Nevertheless, DEB success rate and MACE rate remain favorable. Limitations of this interim analysis include the relatively small sample size and the limited clinical follow-up period. The full PEARL registry is planned to include a larger patient cohort and two years of follow-up. This will also allow us to perform additional subgroup analyses.

**Conclusion**

This interim analysis suggests that the use of the Protégé DEB is safe and effective for PCI of in-stent restenosis and denovo lesions.

**Conflicts of interest**

A research grant was received for the set-up of the PEARL registry. The authors have no conflicts of interest to declare.

**References**